These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 1705137

  • 1. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
    Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ.
    Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
    [Abstract] [Full Text] [Related]

  • 2. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
    Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ.
    Psychopharmacology (Berl); 1992 Dec; 106 Suppl():S68-70. PubMed ID: 1546145
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
    Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, Zimmer RH.
    Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
    [Abstract] [Full Text] [Related]

  • 4. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
    Radat F, Berlin I, Spreux-Varoquaux O, Elatki S, Ferreri M, Puech AJ.
    Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
    Dingemanse J, Kneer J, Wallnöfer A, Kettler R, Zürcher G, Koulu M, Korn A.
    Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects.
    Provost JC, Funck-Brentano C, Rovei V, D'Estanque J, Ego D, Jaillon P.
    Clin Pharmacol Ther; 1992 Oct; 52(4):384-93. PubMed ID: 1424410
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
    Wiesel FA, Raaflaub J, Kettler R.
    Eur J Clin Pharmacol; 1985 Oct; 28(1):89-95. PubMed ID: 3987791
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P, Langley RW, Tavernor S, Pyykkö K, Scheinin M, Szabadi E, Bradshaw CM.
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [Abstract] [Full Text] [Related]

  • 11. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M, Keller HH, Kettler R.
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [Abstract] [Full Text] [Related]

  • 12. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
    Zimmer R.
    Acta Psychiatr Scand Suppl; 1990 Aug; 360():81-3. PubMed ID: 2248084
    [Abstract] [Full Text] [Related]

  • 13. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K.
    J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
    [Abstract] [Full Text] [Related]

  • 14. A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder.
    Lemoine P, Mirabaud C.
    Psychopharmacology (Berl); 1992 Jan; 106 Suppl():S118-9. PubMed ID: 1546124
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
    Patat A, le Coz F, Dubruc C, Gandon JM, Durrieu G, Cimarosti I, Jezequel S, Curet O, Zieleniuk I, Allain H, Rosenzweig P.
    J Clin Pharmacol; 1996 Mar; 36(3):216-29. PubMed ID: 8690815
    [Abstract] [Full Text] [Related]

  • 18. Evaluation and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects.
    Berlin I, Cournot A, Zimmer R, Pedarriosse AM, Manfredi R, Molinier P, Puech AJ.
    Psychopharmacology (Berl); 1990 Mar; 100(1):40-5. PubMed ID: 2296627
    [Abstract] [Full Text] [Related]

  • 19. Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers.
    Scheinin M, Koulu M, Karhuvaara S, Zimmer RH.
    Life Sci; 1990 Mar; 47(16):1491-9. PubMed ID: 2250565
    [Abstract] [Full Text] [Related]

  • 20. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
    Kettler R, Da Prada M, Burkard WP.
    Acta Psychiatr Scand Suppl; 1990 Mar; 360():101-2. PubMed ID: 2248058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.